A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Clinical trial NCT03669718 · UNKNOWN

Trial details

NCT number: NCT03669718
Sponsor: ISA Pharmaceuticals
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Squamous Cell Carcinoma of the Oropharynx HPV16 Positive

Start date: 2018-11-30
Primary completion: 2024-09-01
Enrollment: 194

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.